
    
      The study duration will be displayed in 2 parts as follow:

      Comparative phase (only French patients): 160 +/- 20 days Open label Insuman Implantable
      extension phase (French and European patients): from day 160 up to the grant of Insuman
      implantable marketing authorization
    
  